Department of Pharmacy, North South University, Dhaka, Bangladesh.
BMC Complement Altern Med. 2014 Jan 18;14:31. doi: 10.1186/1472-6882-14-31.
Centella asiatica (C. asiatica) was previously reported to have anti-hyperglycemic effects in animal diabetic model rats. However, its activity on organ and tissue level remains unstudied. Our study aims at exploring the possible effects, C. asiatica extract and insoluble fiber has on carbohydrate absorption, insulin secretion, insulin sensitivity and glucose utilization.
For primary evaluation of anti-hyperglycemic activity, we measured Fasting Blood Glucose and performed Glucose Tolerance Test, in type 2 diabetic rats. To further study the pancreatic effect and glucose utilization, plasma insulin concentration, insulin secreted from isolated rat islets and liver glycogen were assayed. Effect on carbohydrate break down was assayed using intestinal disaccharidase enzyme, α-amylase inhibition assays and Six-Segment study of the GI tract. Effect of C. asiatica on glucose absorption was studied by an in-situ, perfused, intestinal model in rats and by glucose-fiber binding assay. Gastrointestinal motility was seen by a BaSO4 milk traverse test. Additionally, a complete lipid profile assay, after a chronic study, was conducted.
C. asiatica showed no significant change in insulin secretion in-vivo and in isolated rat islets. Additionally, no effect of the extract was seen on liver glycogen deposition. Retarded glucose absorption was seen in the in-situ perfused rat intestinal model at a dose. The extract was also found to inhibit action of both intestinal disaccharidase and α-amylase. This was confirmed, yet again, via the Six Segment study, where sucrose digestion was found to be inhibited throughout the length of the GI Tract. Significant glucose-fiber binding was demonstrated in the in-vitro models. During the chronic study, body mass of C. asiatica treated Type 2 diabetic rats returned to normal and their polydipsic and polyphagic conditions were also improved. Chronic treatment of C. asiatica also improved subject's lipid profile.
A combination of in-vitro, in-vivo and in-situ tests confirmed the anti-hyperglycemic activity of C. asiatica and its tissue level mechanism. Further study is required to fully elucidate the effect this extract or the active compounds have on the individual glucose transporters and the precise mechanism of glucose-fiber binding.
积雪草(C. asiatica)先前被报道在动物糖尿病模型大鼠中具有降血糖作用。然而,其在器官和组织水平上的活性仍未得到研究。我们的研究旨在探索积雪草酸提取物和不溶性纤维对碳水化合物吸收、胰岛素分泌、胰岛素敏感性和葡萄糖利用的可能影响。
为了初步评估抗高血糖活性,我们测量了 2 型糖尿病大鼠的空腹血糖并进行了葡萄糖耐量试验。为了进一步研究胰腺效应和葡萄糖利用,测定了血浆胰岛素浓度、分离大鼠胰岛分泌的胰岛素和肝糖原。使用肠二糖酶、α-淀粉酶抑制试验和胃肠道的六段研究来测定碳水化合物分解的作用。使用大鼠原位灌流肠模型和葡萄糖-纤维结合试验研究积雪草酸对葡萄糖吸收的影响。通过 BaSO4 乳剂穿透试验观察胃肠道动力。此外,在慢性研究后进行了完整的脂质谱分析。
积雪草酸在体内和分离的大鼠胰岛中均未显示胰岛素分泌的显著变化。此外,提取物对肝糖原沉积没有影响。在原位灌流大鼠肠模型中,剂量依赖性地观察到葡萄糖吸收延迟。该提取物还被发现抑制肠二糖酶和α-淀粉酶的作用。这通过六段研究再次得到证实,其中发现蔗糖消化在整个胃肠道长度内受到抑制。在体外模型中证明了显著的葡萄糖-纤维结合。在慢性研究中,积雪草酸治疗 2 型糖尿病大鼠的体重恢复正常,多饮和多食症状也得到改善。积雪草酸的慢性治疗还改善了受试者的血脂谱。
体外、体内和原位试验的组合证实了积雪草酸的抗高血糖活性及其组织水平机制。需要进一步研究以充分阐明该提取物或活性化合物对个体葡萄糖转运体的影响以及葡萄糖-纤维结合的确切机制。